Insulin Lispro Sanofi (Insulin Lispro)

Insulin lispro mimics natural insulin by binding to insulin receptors on muscle and fat cells, triggering a cascade that moves glucose‑transport proteins to the cell surface. This accelerates glucose uptake from the bloodstream and suppresses liver glucose production, producing a rapid decline in blood sugar after meals.

The dose of insulin lispro is individualized. A qualified prescriber determines the amount, timing, and frequency based on the patient’s blood‑glucose readings, carbohydrate intake, and overall treatment regimen. Patients should follow the dosing instructions provided by their healthcare professional and adjust only under medical guidance.

Safety data for insulin lispro in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. Clinicians may prescribe it when the potential benefit outweighs any risk, but close monitoring of maternal and fetal glucose levels is essential. Breastfeeding mothers should consult their physician before use.

To place an order, visit the product page on gnhindia.com, submit an enquiry with the required quantity, and provide institutional or trade credentials. GNH India works with hospitals, pharmacies, and procurement teams worldwide, responding with pricing, availability, shipping details—including cold‑chain logistics if needed—and required import documentation.

Insulin lispro has a faster onset and shorter duration of action compared with regular human insulin, similar to other rapid‑acting analogues such as insulin aspart and insulin glulisine. Clinical studies show comparable efficacy in post‑prandial glucose control, with a slightly lower risk of late‑post‑meal hypoglycaemia for many patients.

Insulin lispro should be stored in a refrigerator at 2‑8 °C (36‑46 °F). Keep the vial or pen in its original carton, protect it from light, and avoid freezing. Once in use, most formulations remain stable at room temperature (up to 25 °C) for a limited period, typically 28‑30 days, as indicated on the label.

Insulin lispro is administered subcutaneously using a sterile syringe, insulin pen, or insulin pump. Injections are usually given within 15 minutes before a meal or immediately after starting to eat. Proper injection technique, rotating sites, and using the correct needle length help minimise skin reactions and ensure consistent absorption.

The most serious risks include severe hypoglycaemia, which can lead to loss of consciousness, seizures, or accidents, and rare allergic reactions such as anaphylaxis. Patients should be educated on recognising early signs of low blood sugar, carrying rapid‑acting glucose sources, and seeking immediate medical attention for any severe reaction.

Insulin lispro is contraindicated in individuals with a known hypersensitivity to insulin lispro or any of its excipients. It should also be avoided in patients experiencing hypoglycaemia until glucose levels are normalised. Clinicians must assess each patient’s medical history, including renal or hepatic impairment, before initiating therapy.